newsfilter
← Latest News
Business Wire·

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

- Company's primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage